Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:8850
Name salivary gland cancer
Definition An oral cavity cancer that is located_in the salivary gland.
Source DiseaseOntology.org
Alt Ids DOID:9148 DOID:8873
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer oral cavity cancer salivary gland cancer


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Vemurafenib salivary gland cancer predicted - sensitive detail...
HRAS mutant Tipifarnib salivary gland cancer predicted - sensitive detail...
RET fusion Selpercatinib salivary gland cancer sensitive detail...
BRAF V600E Dabrafenib + Trametinib salivary gland cancer sensitive detail...
EML4 - ALK Alectinib salivary gland cancer predicted - sensitive detail...
FGFR2 Y375C Erdafitinib salivary gland cancer predicted - sensitive detail...
FGFR2 W72C FGFR2 E565A Erdafitinib salivary gland cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01316757 Phase II Carboplatin + Cetuximab + Erlotinib + Paclitaxel Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed USA 0
NCT01969578 Phase II Bicalutamide + Triptorelin Carboplatin + Paclitaxel Cisplatin + Doxorubicin Androgen Deprivation Therapy in Advanced Salivary Gland Cancer Active, not recruiting NLD | ITA | FRA | DEU | BEL | AUT 2
NCT02091141 Phase II Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Completed USA 0
NCT02538510 Phase Ib/II Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Completed USA 0
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Active, not recruiting USA | FRA | ESP | DEU 14
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | AUS 15
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Completed USA 0
NCT02749903 Phase II Enzalutamide Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers Unknown status USA 0
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed USA 0
NCT03172624 Phase II Ipilimumab + Nivolumab Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Active, not recruiting USA 0
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Active, not recruiting USA 0
NCT03360890 Phase II Docetaxel + Pembrolizumab Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Recruiting USA 0
NCT03781986 Phase Ib/II APG-115 APG-115 in Salivary Gland Cancer Trial Suspended USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT04105543 Phase I CLR 131 CLR 131 Combined With Radiation for Head and Neck Cancer Active, not recruiting USA 0
NCT04209660 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Recruiting USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04704661 Phase I Ceralasertib + Trastuzumab deruxtecan Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Recruiting USA 0
NCT04895735 Phase II Pembrolizumab + Pemetrexed Disodium Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer Recruiting USA 0
NCT05408845 Phase II Docetaxel + Trastuzumab Ado-trastuzumab emtansine Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer Recruiting USA 0
NCT05608876 Phase II Tigilanol tiglate A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer Recruiting GBR | AUS 0
NCT05669664 Phase II Darolutamide + Leuprolide Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers Recruiting USA 0
NCT05884320 Phase II Sacituzumab govitecan-hziy Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Salivary Gland Cancers Recruiting USA 0